Text | Jin Wei
What happened to the hundred billion white horse?
Half an hour before the noon close today (January 19), Changchun High-tech suddenly flashed and fell to a halt, less than 20 minutes before and after, as of now, Changchun High-tech is reported at 227 yuan, with a total market value of 92.1 billion. Compared with the previous trading day, the market value shrank by 10.2 billion.
The K line shows that Changchun Gaoxin has been in a downward channel in recent months, in May 2021, Changchun Gaoxin stock price once rose to 523 yuan, the total market value reached 211.8 billion, and now the market value has been cut, shrinking by more than 100 billion, and the stock price has hit a new low in 22 months.
According to the latest 150,000 shareholders, the per capita loss of nearly 70,000 yuan in a single day, the sudden plunge, what happened to Changchun High-tech?
On the news side, there are mainly media reports that Changchun High-tech recombinant human growth hormone has been included in the Guangdong drug collection. According to the notice learned on the website of Guangdong Provincial Drug Trading Center on the "Guangdong Alliance Diclofenac and Other Drugs Centralized Procurement Documents", a number of recombinant human growth hormone is included in the collection catalogue, including Changchun Jinsai Pharmaceutical Co., Ltd., a subsidiary of Changchun High-tech Holdings, which is recombinant human growth hormone injection (Sinopharm S20050025).
Previously, Changchun Gaoxin announced on January 12 that Changchun Kinsey Pharmaceutical Co., Ltd., a holding subsidiary of the company, received the "Notice of Approval of Drug Supplement Application" approved by the State Food and Drug Administration, approving the approved indications for Kinsey Pharmaceutical to increase the domestic same variety of human growth hormone for injection, including: for short stature in children caused by cartilage insufficiency; for growth disorders in girls caused by hypogonadism (Turner syndrome); and for adult short bowel syndrome receiving nutritional support.
According to the data, Changchun High-tech takes biopharmaceuticals, the production and sales of proprietary Chinese medicines, and real estate development as the leading industries, supplemented by infrastructure construction and property management in the development zone. Changchun High-tech 2021 third quarter report shows that the company's main revenue of 8.239 billion yuan, up 28.75% year-on-year; net profit attributable to the mother of 3.147 billion yuan, up 39.25% year-on-year.
Changchun high-tech is the leader of growth hormone, before the brokerage research report said that Changchun high-tech domestic market space is large, the competition pattern is good, through the latest two investments, the company will accelerate the development of the neonatal field and the field of psychiatric nerves, enhance technical reserves, optimize product structure, enhance core competitiveness, and promote the company's healthy and sustainable development.
Previously, Changchun High-tech was on the collection list, and the stock price had dived. In addition, Changchun High-tech's second largest shareholder Jin Lei reduced the company's shares, which had a greater impact on the company, from the third quarterly report shows that institutional funds have fled, and the holding institutions have changed from more than a thousand to more than 200.
In the scale of Changchun high-tech shareholder group, investors have a lot of discussion about Changchun high-tech, some investors said, the main reason is the reason for the landing of the collection, has been staged a diving before, the collection means fierce price competition, but on the other hand also means that the winning enterprises can get more market space. Some investors said that the collection alone would not scare the company to stop, and there may be other reasons.
What are your views on the Changchun high-tech drop stop, welcome to leave a message below.